Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain. This mutation is predicted to result in a substitution of cysteine by tyrosine at amino acid residue 1156 (C1156Y). Her tumor di...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:N Engl J Med
Autors principals: Shaw, Alice T., Friboulet, Luc, Leshchiner, Ignaty, Gainor, Justin F., Bergqvist, Simon, Brooun, Alexei, Burke, Benjamin J., Deng, Ya-Li, Liu, Wei, Dardaei, Leila, Frias, Rosa L., Schultz, Kate R., Logan, Jennifer, James, Leonard P., Smeal, Tod, Timofeevski, Sergei, Katayama, Ryohei, Iafrate, A. John, Le, Long, McTigue, Michele, Getz, Gad, Johnson, Ted W., Engelman, Jeffrey A.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4773904/
https://ncbi.nlm.nih.gov/pubmed/26698910
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1508887
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars